Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

Pfizer’s gruelling trek to bring EGFR inhibitor dacomitinib to market has finally paid off, with the FDA approving it as a first-line therapy for non-small cell lung cancer ... NSCLC). The second-generation EGFR tyrosine kinase inhibitor has been shown

Latest news

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting. ... alongside AZ’s EGFR inhibitor Iressa

  • AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

    AstraZeneca’s blockbuster-in-waiting lung cancer treatment Tagrisso has just been approved in Japan as a first-line treatment for patients with inoperable or recurrent epidermal growth factor receptor (EGFR) ... recurrent NSCLC that is resistant to

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

  • AZ’s immuno-oncology combo fails another lung cancer trial AZ’s immuno-oncology combo fails another lung cancer trial

    There is no doubt, however, that the study raises another question mark over the role of CTLA4 inhibitor tremelimumab. ... There was better news for AZ in cancer last week, after the company picked up FDA approval for its EGFR inhibitor Tagrisso

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a compelling argument that the drug should be use ahead of other dugs in the class in ... using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung

More from news
Approximately 1 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics